The value of cell‐free DNA for molecular pathology
Open Access
- 30 January 2018
- journal article
- review article
- Published by Wiley in The Journal of Pathology
- Vol. 244 (5), 616-627
- https://doi.org/10.1002/path.5048
Abstract
Over the past decade, advances in molecular biology and genomics techniques have revolutionized the diagnosis and treatment of cancer. The technological advances in tissue profiling have also been applied to the study of cell‐free nucleic acids, an area of increasing interest for molecular pathology. Cell‐free nucleic acids are released from tumour cells into the surrounding body fluids and can be assayed non‐invasively. The repertoire of genomic alterations in circulating tumour DNA (ctDNA) is reflective of both primary tumours and distant metastatic sites, and ctDNA can be sampled multiple times, thereby overcoming the limitations of the analysis of single biopsies. Furthermore, ctDNA can be sampled regularly to monitor response to treatment, to define the evolution of the tumour genome, and to assess the acquisition of resistance and minimal residual disease. Recently, clinical ctDNA assays have been approved for guidance of therapy, which is an exciting first step in translating cell‐free nucleic acid research tests into clinical use for oncology. In this review, we discuss the advantages of cell‐free nucleic acids as analytes in different body fluids, including blood plasma, urine, and cerebrospinal fluid, and their clinical applications in solid tumours and haematological malignancies. We will also discuss practical considerations for clinical deployment, such as preanalytical factors and regulatory requirements. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- University of Cambridge
- Victorian Cancer Agency
- National Breast Cancer Foundation
- Cancer Research UK
This publication has 175 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerThe New England Journal of Medicine, 2013
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Detection and quantification of rare mutations with massively parallel sequencingProceedings of the National Academy of Sciences of the United States of America, 2011
- Origin and quantification of circulating DNA in mice with human colorectal cancer xenograftsNucleic Acids Research, 2010
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- Digital PCR for the molecular detection of fetal chromosomal aneuploidyProceedings of the National Academy of Sciences of the United States of America, 2007
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004